Delivery technologies for women’s health applications
Delivery technologies for women’s health applications
复制标题
DOI：
10.1038/s44222-023-00040-w
复制
发表时间：
2023-03
期刊：
影响因子：
--
通讯作者：
K. Swingle;A. Ricciardi;W. Peranteau;Michael J. Mitchell
中科院分区：
文献类型：
--
作者：
K. Swingle;A. Ricciardi;W. Peranteau;Michael J. Mitchell
治疗与妇女健康有关的疾病，包括生殖道和妊娠障碍，面临着独特的挑战和微环境，如阴道粘膜和胎盘，纳米技术和生物材料给药技术可能会克服这些挑战。在这里，我们讨论治疗性纳米颗粒和生物材料系统的设计和优化，以提供治疗非怀孕和怀孕妇女疾病的药物，包括阴道感染、生殖道疾病、妊娠疾病和胎儿先天性疾病。我们重点介绍了如何针对特定的给药途径，如阴道、宫内和腹膜给药，设计药物输送系统，以穿透生物屏障，如阴道粘膜，并在感兴趣的部位提供持续和有效的药物输送。尽管到目前为止，这些给药系统主要是在临床前环境中探索的，但在给药技术中实施针对妇女的设计考虑将使它们能够优化和临床转化为治疗妇女的健康状况。
The treatment of women’s health-related conditions, including reproductive tract and pregnancy disorders, faces distinct challenges and microenvironments, such as the vaginal mucosa and the placenta, which may be overcome by nanotechnology- and biomaterials-based drug delivery technologies. Here, we discuss the design and optimization of therapeutic nanoparticle and biomaterial systems to deliver drugs for the treatment of conditions in non-pregnant and pregnant women, including vaginal infections, reproductive tract disorders, pregnancy conditions and fetal congenital disorders. We highlight how drug delivery systems can be engineered for specific administration routes such as vaginal, in utero and intraperitoneal administration, to penetrate biological barriers such as the vaginal mucosa, and to provide sustained and efficient drug delivery at the site of interest. Although these delivery systems have mainly been explored in preclinical settings thus far, implementing women-specific design considerations in delivery technologies will allow their optimization and clinical translation for the treatment of women’s health conditions.